… Collectively, these data suggest that actionable mutations detected in ctDNA may be helpful,
but their absence does not yet reliably exclude a positive tissue biopsy or clinical benefit. …

… had a long-term benefit of nivolumab. In conclusion, NGS analysis of ctDNA allows the
early detection of tumor response and long-term clinical benefit with nivolumab in NSCLC. …

… Inhibitors of programmed death 1 (PD-1) protein or its ligand (PD-L1) have shown remarkable
clinical benefits in many cancers.69 One emerging biomarker for response to anti-PD-1 or …

… studies 37 ,40 -42 have demonstrated that bTMB can be accurately and reproducibly
measured and is associated with clinical benefit of ICIs in non-small cell lung cancer (NSCLC), …

… Recent studies suggest a role for circulating tumor DNA (ctDNA) in monitoring response to
ICI, but uncertainty exists in the generalizability of these studies. Here, the role of ctDNA for …

… Baseline ctDNA concentration correlated with progression-free survival, overall survival,
clinical response and clinical benefit. This association became stronger when considering …

… a nominal survival benefit from the … tumor DNA (ctDNA), arises from somatic tumor DNA
fragments released into the blood circulation during cell death [5]. ctDNA is highly tumor specific …

… The accuracies of serial ctDNA analysis and clinical risk in estimating … tumor DNA has
a higher AUC than clinical risk, but the combination of serial ctDNA analysis and clinical risk …

… Clinicians rely on scans and … tumor DNA (ctDNA) has great potential as a biomarker and
is intensively investigated in the plasma. Circulating tumor DNA is small, tumor-specific DNA …

… tumor DNA (ctDNA) in plasma and its application in clinical immunotherapy. In healthy
individuals, the majority of cell-free DNA (… tumor mutational burden as a predictor of clinical benefit …